Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A second phase 2 complementary study of MP0250 in combination with Pomalidomide and dexamethasone in patients with relapsed or refractory MM who have failed at least two lines of therapy

Next Previous
Search
Trial Profile

A second phase 2 complementary study of MP0250 in combination with Pomalidomide and dexamethasone in patients with relapsed or refractory MM who have failed at least two lines of therapy

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; MP 0250 (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Feb 2020 According to a Molecular Partners AG media release, the company announced it will not start this study in alignment with company's corporate strategy to pursue combination data in collaboration with a partner
    • 06 Feb 2020 Status changed from planning to withdrawn prior to enrolment, according to a Molecular Partners AG media release.
    • 09 May 2019 According to a Molecular Partners AG media release, the company aims to open recruitment in this trial in 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top